GoKawiilSign up to see the future, today Can’t-miss innovations from the bleeding edge of science and tech Email address Sign Up Thank you!
Scientists continue to investigate the potential clinical use of psilocybin, the psychoactive compound in psychedelic mushrooms, for everything from a potential anti-aging treatment to therapy for depression and anxiety.
Some have even suggested it could even be an effective treatment for Alzheimer’s disease, a devastating neurodegenerative condition that affects more than seven million Americans.
Case in point, a recent case report — published in the journal Frontiers in Neuroscience Neuropharmacology by a small team of researchers in Brazil —describes an experiment involving a woman, in her 80s and who had been suffering from Alzheimer’s disease for ten years, being given a staggeringly high dose of psilocybin.
After being given “five grams of orally administered psilocybin-containing mushrooms” — well over twice a typical recreational dose and orders of magnitude more than is conventionally prescribed in clinical settings — the team says that the woman experienced what could crudely be described as a reawakening.
In a matter of “days and weeks” — the report remains vague on the exact timeline — the patient went from “marked hypofunction and predominantly monosyllabic speech” to restored “urinary continence,” improved mobility, “increased emotional responsiveness” and “sustained social interaction.” Even her “contextual memory retrieval” allegedly improved.
The octogenarian must’ve gone through a lot, spending hours sweating profusely in a “deep sleep-like state” following the administering of the drug. The woman was even given a second, three-gram dose after a month due to “persistence of clinically meaningful improvements.” (Futurism has reached out to the authors about the woman’s ability to consent to the eyebrow-raising treatment given her state.)
To be perfectly clear, the whole thing is pretty dodgy, despite getting considerable breathless media coverage in the New York Post and the Dallas Express, which called the report a “breakthrough.” Beyond the hard-to-miss absence of scientific rigor and consent issues, the “report does not show that psychedelics reverse Alzheimer’s disease,” as University of Sheffield neuroscience PhD candidate Rahul Sidhu wrote in an essay for The Conversation,
The report wasn’t a controlled clinical trial, for starters, and its single subject’s diagnosis wasn’t “confirmed using biomarkers.” There was also no control group, no standardized testing of memory and thinking before the woman was given the shrooms, and observations were “largely based on reports from caregivers and family members,” Sidhu cautioned.
In short, the case report appears to be little more than a wild story of an elderly woman being given an enormous dose of drugs. In the words of the case report itself, it was an intervention that was “exploratory and observational in nature.”
... continue reading